Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.30 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20034186 | 0.95 | LMNA (0.82) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL14601670 | 0.95 | CYP2C19 (0.86) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL19915482 | 0.95 | CYP2C19 (0.86) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL20350848 | 0.93 | LMNA (0.86) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL10329899 | 0.92 | LMNA (0.88) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL20829072 | 0.89 | LMNA (0.76) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL24114250 | 0.88 | CYP2C19 (0.66) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL24169901 | 0.88 | LMNA (0.73) | CYP2C19HIF1ALMNAEGFRSRC | |
| Iohexol SCHEMBL37920 | 0.88 | CYP2C19 (1.00) | CYP2C19HIF1ALMNAEGFRSRC | |
| Iohexol SCHEMBL26501 | 0.88 | CYP2C19 (1.00) | CYP2C19HIF1ALMNAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911041-B2 | Embolic compositions | MICROVENTION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210330334-A1 | EMBOLIC COMPOSITIONS | MICROVENTION, INC. | 2021-10-28 | — | — | US | disclosed |
| US-11051826-B2 | Embolic compositions | MICROVENTION, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20190298388-A1 | EMBOLIC COMPOSITIONS | MICROVENTION, INC. | 2019-10-03 | — | — | US | disclosed |
| US-10350311-B2 | Iohexol powder and method of using the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350311-B2 | Iohexol powder and method of using the same | PPIP5K2, SLC5A11, IP6K2 | CYP2C19 545/4885HIF1A 2076/4885LMNA 3959/4885 |
| US-11911041-B2 | Embolic compositions | PLG, FGB, TNNC1 | CYP2C19 3137/4885HIF1A 225/4885LMNA 182/4885 |
| US-20210330334-A1 | EMBOLIC COMPOSITIONS | PLG, FGB, TNNC1 | CYP2C19 3137/4885HIF1A 225/4885LMNA 182/4885 |
| US-20190298388-A1 | EMBOLIC COMPOSITIONS | PLG, FGB, TNNC1 | CYP2C19 3137/4885HIF1A 225/4885LMNA 182/4885 |
| US-11051826-B2 | Embolic compositions | PLG, FGB, TNNC1 | CYP2C19 3137/4885HIF1A 225/4885LMNA 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.